GW Pharmaceuticals PLC- (NASDAQ:GWPH) insider Douglas B. Snyder sold 3,756 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $13.88, for a total value of $52,133.28. Following the completion of the transaction, the insider now directly owns 79,164 shares in the company, valued at approximately $1,098,796.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Douglas B. Snyder also recently made the following trade(s):
- On Tuesday, July 9th, Douglas B. Snyder sold 4,968 shares of GW Pharmaceuticals PLC- stock. The shares were sold at an average price of $14.42, for a total value of $71,638.56.
NASDAQ GWPH traded down $4.70 during trading on Wednesday, hitting $155.12. 363,800 shares of the company’s stock traded hands, compared to its average volume of 447,154. The business’s fifty day moving average price is $166.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.59 and a current ratio of 8.31. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $196.00. The firm has a market cap of $4.72 billion, a price-to-earnings ratio of -14.69 and a beta of 2.25.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.74) by $0.96. GW Pharmaceuticals PLC- had a negative net margin of 101.45% and a negative return on equity of 38.09%. The business had revenue of $72.04 million during the quarter, compared to analyst estimates of $37.28 million. During the same period in the prior year, the business posted ($0.25) earnings per share. The company’s revenue was up 2096.3% on a year-over-year basis. On average, sell-side analysts anticipate that GW Pharmaceuticals PLC- will post -4.51 earnings per share for the current year.
GWPH has been the topic of a number of research analyst reports. Oppenheimer increased their target price on GW Pharmaceuticals PLC- from $234.00 to $239.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Zacks Investment Research raised GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $192.00 target price on the stock in a research note on Monday. JPMorgan Chase & Co. upgraded shares of GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a research report on Wednesday, May 8th. Guggenheim restated a “buy” rating and set a $222.00 price target (up from $186.00) on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, May 7th. Finally, ValuEngine lowered shares of GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research report on Monday. Two equities research analysts have rated the stock with a sell rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. GW Pharmaceuticals PLC- currently has a consensus rating of “Buy” and an average price target of $209.82.
Several institutional investors have recently bought and sold shares of GWPH. ETF Managers Group LLC purchased a new stake in shares of GW Pharmaceuticals PLC- during the second quarter worth about $99,346,000. Marshall Wace North America L.P. boosted its holdings in shares of GW Pharmaceuticals PLC- by 1,564.3% during the first quarter. Marshall Wace North America L.P. now owns 316,899 shares of the biopharmaceutical company’s stock worth $53,419,000 after purchasing an additional 297,858 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of GW Pharmaceuticals PLC- by 80.4% during the first quarter. Victory Capital Management Inc. now owns 408,940 shares of the biopharmaceutical company’s stock worth $68,935,000 after purchasing an additional 182,210 shares during the period. FMR LLC boosted its holdings in shares of GW Pharmaceuticals PLC- by 25,456.4% during the first quarter. FMR LLC now owns 134,682 shares of the biopharmaceutical company’s stock worth $22,704,000 after purchasing an additional 134,155 shares during the period. Finally, Sio Capital Management LLC boosted its holdings in shares of GW Pharmaceuticals PLC- by 990.5% during the second quarter. Sio Capital Management LLC now owns 124,164 shares of the biopharmaceutical company’s stock worth $21,405,000 after purchasing an additional 112,778 shares during the period. Institutional investors own 78.92% of the company’s stock.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Featured Story: Beta
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.